RESULTS: 1) The diameter of MPS-NSSLs-SPANb particles was 105.8 ± 0.8 nm, the encapsulation efficiency of NSSLs-SPANb to MPS was 92.5 ± 0.3%. MPS-NSSLs-SPANb could be stored at 4°C for no less than 12 weeks. 2) ELISA showed that MPS-NSSLs-SPANb could actively bind with SP-A antigen. Small animal imaging and pharmacokinetic study of MPS-NSSLs-SPANb in rats showed that the peak value of MPS in lung after MPS-NSSLs-SPANb injection was 4.58-fold (Ce = 4.58) of that after MPS injection, and the AUC0-12h after MPS-NSSLs-SPANb injection was 17.78-fold (Re = 17.78) of that after MPS injection, indicating that MPS-NSSLs-SPANb had good lung-targeting properties. 3) In rats with bleomycin-induced lung injury, MPS-NSSLs-SPANb significantly reduced the level of TNF-α, IL-8, and TGF-β1 in rat bronchoalveolar lavage fluid (BALF) and the expression of NK-κB in the lung tissues, thereby alleviating the injuries of the lung and increasing the survival proportion of rats after lung damage.